Publications des événements indésirables

Adenopathy is any disease or inflammation that involves glandular tissue or lymph nodes. The term is usually used to refer to lymphadenopathy or swollen lymph nodes.

Unilateral axillary adenopathy induced by COVID-19 vaccine: US follow-up evaluation

Axillary Adenopathy in Patients with Recent Covid-19 Vaccination: A New Diagnostic Dilemma

Incidence of Axillary Adenopathy in Breast Imaging After COVID-19 Vaccination

Adenopathy Following COVID-19 Vaccination

COVID-19 Vaccination–Associated Axillary Adenopathy: Imaging Findings and Follow-Up Recommendations in 23 Women

Axillary Adenopathy in Patients with Recent Covid-19 Vaccination: A New Diagnostic Dilemma

Incidence of Axillary Adenopathy in Breast Imaging After COVID-19 Vaccination

Unilateral axillary adenopathy in the setting of COVID-19 vaccine: Follow-up

Surveillance for Adverse Events After COVID-19 mRNA Vaccination

Assessment of Allergic and Anaphylactic Reactions to mRNA COVID-19 Vaccines With Confirmatory Testing in a US Regional Health System

Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine — United States, December 14–23, 2020

Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA

Practical handling of allergic reactions to COVID-19 vaccines

Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report

The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach

Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination

Prolonged Anaphylaxis to Pfizer Coronavirus Disease 2019 Vaccine: A Case Report and Mechanism of Action

Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine — United States, December 21, 2020–January 10, 2021

Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine — United States, December 14–23, 2020

Sex differences in the incidence of anaphylaxis to LNP-mRNA COVID-19 vaccines Author links open overlay panel

Association of Self-reported High-Risk Allergy History With Allergy Symptoms After COVID-19 Vaccination

Anaphylaxis after Moderna COVID-19 vaccine

CoronaVac COVID-19 Vaccine-Induced Anaphylaxis: Clinical Characteristics and Revaccination Outcomes

Anaphylaxis After the Covid-19 Vaccine in a Patient With Cholinergic Urticaria

Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases – practical recommendations. A position statement of ETFAD with external experts

Allergic Reactions After COVID-19 Vaccination—Putting Risk Into Perspective

IgE-mediated allergy to polyethylene glycol (PEG) as a cause of anaphylaxis to mRNA COVID-19 vaccines

Allergic reactions to COVID-19 vaccines: statement of the Belgian Society for Allergy and Clinical Immunology

Allergic reactions and adverse events associated with administration of mRNA-based vaccines. A health-care system experience

High anaphylaxis rates following vaccination with the Pfizer BNT162b2 mRNA vaccine against COVID-19 in Japanese healthcare workers: a secondary analysis of initial post-approval safety data

Allergy to Polyethilenglicole of Anti-SARS CoV2 Vaccine Recipient: A Case Report of Young Adult Recipient and the Management of Future Exposure to SARS-CoV2

Acute Allergic Reactions to mRNA COVID-19 Vaccines

Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine

Allergenic components of the mRNA-1273 vaccine for COVID-19: Possible involvement of polyethylene glycol and IgG-mediated complement activation

Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine

Covid-19-vaksiner gir økt risiko for anafylaksi

Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report

Reported orofacial adverse effects of COVID-19 vaccines: The knowns and the unknowns

Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines

Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA

Anaphylaxis associated with the mRNA COVID-19 vaccines: Approach to allergy investigation 

Relationship between pre-existing allergies and anaphylactic reactions post mRNA COVID-19 vaccine administration

Immunization practices and risk of anaphylaxis: a current update, comprehensive of COVID-19 vaccination data

Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US—December 14, 2020-January 18, 2021

Reports of anaphylaxis after coronavirus disease 2019 vaccination, South Korea, 26 February to 30 April 2021

Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine — United States, December 21, 2020–January 10, 2021

Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine — United States, December 14–23, 2020

Allergic reactions to the first COVID-19 vaccine: A potential role of polyethylene glycol?

Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine

COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee

ANCA glomerulonephritis and vasculitis are rare autoimmune diseases, meaning that the body’s own immune system injures its cells and tissues. Vasculitis is a disorder where there is destruction of blood vessels by inflammation that affects both arteries and veins. Glomerulonephritis is a kind of kidney disease caused by inflammation in the glomeruli (the small blood vessels) in the kidneys.

ANCA glomerulonephritis after the Moderna COVID-19 vaccination

Aphasia seven days after second dose of an mRNA-based SARS-CoV-2 vaccine

Reactive arthritis after COVID-19 vaccination

Surveillance for Adverse Events After COVID-19 mRNA Vaccination

Neurological autoimmune diseases following vaccinations against SARS-CoV-2: a case series

Severe autoimmune hemolytic anemia following receipt of SARS-CoV-2 mRNA vaccine

Autoimmune- and complement-mediated hematologic condition recrudescence following SARS-CoV-2 vaccination

Reactivation of BCG vaccination scars after vaccination with mRNA-Covid-vaccines: two case reports

Bell’s palsy is an unexplained episode of facial muscle weakness or paralysis. It begins suddenly and worsens over 48 hours. This condition results from damage to the facial nerve (the 7th cranial nerve). Pain and discomfort usually occur on one side of the face or head. Bell’s palsy can strike anyone at any age.

Bell’s palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study

Bell’s palsy after inactivated COVID-19 vaccination in a patient with history of recurrent Bell’s palsy: A case report Yu BY, Cen LS, Chen T, Yang TH. Bell’s palsy after inactivated COVID-19 vaccination in a patient with history of recurrent Bell’s palsy: A case report. World J Clin Cases 2021; 9(27): 8274-8279 [PMID: 34621891 DOI: 10.12998/wjcc.v9.i27.8274]

Left Bell’s palsy following the first dose of mRNA-1273 SARS-CoV-2 vaccine: A case report

Bilateral Facial Nerve Palsy and COVID-19 Vaccination: Causation or Coincidence?

Adverse event reporting and Bell’s palsy risk after COVID-19 vaccination

Bell’s palsy following a single dose of mRNA SARS-CoV-2 vaccine: a case report

Bell’s palsy following COVID-19 vaccination with high CSF antibody response

Eine akute Fazialisparese als mögliche Impfkomplikation bei einer Impfung gegen SARS-CoV-2

Bell’s palsy following COVID-19 vaccination: a case report

Bell’s Palsy After 24 Hours of mRNA-1273 SARS-CoV-2 Vaccine

Bell’s palsy following COVID-19 vaccination

The association between COVID-19 vaccination and Bell’s palsy

Bell’s palsy following COVID-19 vaccination: a case report

Bell’s Palsy after second dose of Pfizer COVID-19 vaccination in a patient with history of recurrent Bell’s palsy

Bell’s palsy and SARS-CoV-2 vaccines—an unfolding story

Bilateral facial palsy, AKA Facial Diplegia, is defined as facial paralysis or paresis affection both sides of the face, with onset being either completely simultaneous or the second side being affected within 30 days of the first side.

A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine

HLA-B27–associated uveitis is most often characterized by recurrent anterior ocular inflammation in one eye at a time. Bilateral simultaneous disease is much less common and behaves differently from unilateral disease, with fewer recurrences.

Bilateral uveitis after inoculation with COVID-19 vaccine: A case report 

Analysis of Staphylococcus aureus Transcriptome in Pediatric Soft Tissue Abscesses and Comparison to Murine Infections 

Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals 

Emergence of COVID-19 variants among ChAdOx1 nCoV-19 (recombinant) vaccine recipients 

Bursitis is inflammation of a bursa. A bursa is a closed, fluid-filled sac that works as a cushion and gliding surface to reduce friction between tissues of the body. The major bursae (this is the plural of bursa) are located next to the tendons near the large joints, such as in the shoulders, elbows, hips, and knees.

Vasculitis and bursitis on [18F]FDG-PET/CT following COVID-19 mRNA vaccine: post hoc ergo propter hoc? 

The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: A monocentric experience 

Coronavirus disease 2019 vaccine mimics lymph node metastases in patients undergoing skin cancer follow-up: A monocentre study 

COVID-19 vaccine-related axillary lymphadenopathy in breast cancer patients: Case series with a review of literature 

Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report 

Lung squamous cell carcinoma with hemoptysis after vaccination with tozinameran (BNT162b2, Pfizer-BioNTech) 

Systemic capillary leak syndrome after ChAdOx1 nCOV-19 (Oxford–AstraZeneca) vaccination 

Fatal Systemic Capillary Leak Syndrome after SARS-CoV-2 Vaccination in Patient with Multiple Myeloma 

A systematic review of cases of CNS demyelination following COVID-19 vaccination 

COVID-19 mRNA vaccination leading to CNS inflammation: a case series 

Varicella-zoster and herpes simplex virus reactivation post-COVID-19 vaccination: a review of 40 cases in an International Dermatology Registry

Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections 

Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year 

RETRACTED: Why are we vaccinating children against COVID-19? 

COVID-19 in Children: Clinical Manifestations and Pharmacologic Interventions Including Vaccine Trials 

Safety and tolerability of the COVID-19 messenger RNA vaccine in adolescents with juvenile idiopathic arthritis treated with tumor necrosis factor inhibitors 

Autopsy Findings and Causality Relationship between Death and COVID-19 Vaccination: A Systematic Review 

Postmortem investigation of fatalities following vaccination with COVID-19 vaccines 

Myocarditis-induced Sudden Death after BNT162b2 mRNA COVID-19 Vaccination in Korea: Case Report Focusing on Histopathological Findings 

Deaths associated with newly launched SARS-CoV-2 vaccination 

Bell’s palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study  

Postmortem investigation of fatalities following vaccination with COVID-19 vaccines  (post Mortem investigation)

Brain death in a vaccinated patient with COVID-19 infection  (Brain)

Myocarditis-induced Sudden Death after BNT162b2 mRNA COVID-19 Vaccination in Korea: Case Report Focusing on Histopathological Findings 

Post-mortem findings in vaccine-induced thrombotic thombocytopenia  (thrombocytopenia)

Fatal cerebral venous sinus thrombosis after COVID-19 vaccination  (cerebral)

An Insight into the Role of Postmortem Immunohistochemistry in the Comprehension of the Inflammatory Pathophysiology of COVID-19 Disease and Vaccine-Related Thrombotic Adverse Events: A Narrative Review  (post-mortem, thrombosis)

Fatal vaccine-induced immune thrombotic thrombocytopenia (VITT) post Ad26.COV2.S: first documented case outside US  (VITT)

Fatal Systemic Capillary Leak Syndrome after SARS-CoV-2 Vaccination in Patient with Multiple Myeloma 

Vaccine Induced Immune Thrombotic Thrombocytopenia Causing a Severe Form of Cerebral Venous Thrombosis With High Fatality Rate: A Case Series

Intracerebral Hemorrhage due to Thrombosis with Thrombocytopenia Syndrome after Vaccination against COVID-19: the First Fatal Case in Korea Jae-Ki Choi,1,* Sunghan Kim,2,* Seo Ree Kim,3 Jong-Youl Jin,3 Seon Woong Choi,2 Hoon Kim,2 Jin-H 

Fatal hjerneblødning etter covid-19-vaksine 

COVID-19 Vaccine and Death: Causality Algorithm According to the WHO Eligibility Diagnosis 

Post-mortem findings in vaccine-induced thrombotic thombocytopenia 

Fatal hjerneblødning etter covid-19-vaksine 

Depression following ChAdOx1-S/nCoV-19 vaccine 

Effective DNA damage response after acute but not chronic immune challenge: SARS-CoV-2 vaccine versus Systemic Lupus Erythematosus 

Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines 

SARS-CoV-2 anti–spike antibodies after vaccination in pediatric heart transplantation: A first report 

Pediatric COVID-19 patients in South Brazil show abundant viral mRNA and strong specific anti-viral responses 

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase 

Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients 

SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group 

« Encephalopathy » means damage or disease that affects the brain. It happens when there’s been a change in the way your brain works or a change in your body that affects your brain. Those changes lead to an altered mental state, leaving you confused and not acting like you usually do.

A case of acute encephalopathy and non-ST segment elevation myocardial infarction following mRNA-1273 vaccination: possible adverse effect? 

Post-COVID-19 vaccine acute hyperactive encephalopathy with dramatic response to methylprednisolone: A case report 

Encephalitis is inflammation of the brain. There are several causes, including viral infection, autoimmune inflammation, bacterial infection, insect bites and others. Sometimes there is no known cause.

Autoimmune encephalitis following ChAdOx1-S SARS-CoV-2 vaccination 

Postvaccinal Encephalitis after ChAdOx1 nCov-19 

Acute disseminated encephalomyelitis after SARS-CoV-2 vaccination 

Central retinal vein occlusion after mRNA SARS-CoV-2 vaccination: A case report  (with central retinal vein inclusion)

Ocular Adverse Events After COVID-19 Vaccination (Ocular)

Bilateral Acute Macular Neuroretinopathy After Vaccination Against SARS-CoV-2 

Transient Oculomotor Palsy Following the Administration of the Messenger RNA-1273 Vaccine for SARS-CoV-2 Diplopia Following the COVID-19 Vaccine 

Acute abducens nerve palsy following COVID-19 vaccination 

Acute-onset central serous retinopathy after immunization with COVID-19 mRNA vaccine 

Gastroparesis After Pfizer-BioNTech COVID-19 Vaccination 

Unilateral axillary adenopathy induced by COVID-19 vaccine: US follow-up evaluation 

Two Cases of Graves’ Disease Following SARS-CoV-2 Vaccination: An Autoimmune/Inflammatory Syndrome Induced by Adjuvants 

Facial Diplegia: A Rare, Atypical Variant of Guillain-Barré Syndrome and Ad26.COV2.S Vaccine 

A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine 

Facial nerve palsy following the administration of COVID-19 mRNA vaccines: analysis of a self-reporting database 

Sequential contralateral facial nerve palsies following COVID-19 vaccination first and second doses 

Association of COVID-19 Vaccination and Facial Nerve Palsy 

Facial nerve palsy following the administration of COVID-19 mRNA vaccines: analysis of a self-reporting database 

Guillain-Barré (Ghee-YAN Bah-RAY) syndrome (GBS) happens when a person’s own immune system harms their body’s nerves. This harm causes muscle weakness and sometimes paralysis.

Miller-Fisher Syndrome and Guillain-Barre Syndrome overlap syndrome in a patient post Oxford-AstraZeneca SARS-CoV-2 vaccination 

Clinical Variant of Guillain–Barre Syndrome With Prominent Facial Diplegia After AstraZeneca Coronavirus Disease 2019 Vaccine 

SARS-CoV-2 vaccinations may not only be complicated by GBS but also by distal small fibre neuropathy 

Guillain-Barré syndrome following the first dose of SARS-CoV-2 vaccine: A temporal occurrence, not a causal association 

Axonal-Variant Guillian-Barre Syndrome Temporally Associated With mRNA-Based Moderna SARS-CoV-2 Vaccine 

Guillain–Barré Syndrome Variant Occurring after SARS-CoV-2 Vaccination 

Guillain-Barré Syndrome in an Australian State Using Both mRNA and Adenovirus-Vector SARS-CoV-2 Vaccines 

Guillain–Barré syndrome after SARS-CoV-2 vaccination in a patient with previous vaccine-associated Guillain–Barré syndrome 

A Rare Variant of Guillain-Barre Syndrome Following Ad26.COV2.S Vaccination 

A variant of Guillain-Barre syndrome after SARS-CoV-2 vaccination: AMSAN 

A case of sensory ataxic Guillain–Barré syndrome with immunoglobulin G anti-GM1 antibodies following the first dose of mRNA COVID-19 vaccine BNT162b2 (Pfizer) 

Bilateral facial weakness with paraesthesia variant of Guillain-Barré syndrome following Vaxzevria COVID-19 vaccine 

Guillan-Barré Syndrome after First Vaccination Dose against COVID-19: Case Report 

COVID-19 vaccine causing Guillain-Barre syndrome, a rare potential side effect 

Neurological Complications of COVID-19: Guillain-Barre Syndrome Following Pfizer COVID-19 Vaccine 

A Rare Case of Guillain-Barré Syndrome following COVID-19 Vaccination 

Guillain‐Barré syndrome presenting with facial diplegia following COVID‐19 vaccination in two patients 

Guillain–Barrè syndrome following COVID-19 vaccine mRNA-1273: a case report 

Guillain-Barré Syndrome following ChAdOx1-S/nCoV-19 Vaccine 

Guillain-Barré Syndrome After COVID-19 Vaccination in an Adolescent 

Rate of Recurrent Guillain-Barré Syndrome After mRNA COVID-19 Vaccine BNT162b2 

A case of Guillain–Barre syndrome following Pfizer COVID-19 vaccine 

Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome, February-July 2021 

Adenovirus COVID-19 Vaccines and Guillain–Barré Syndrome with Facial Paralysis 

Guillain-Barré syndrome following BNT162b2 COVID-19 vaccine 

Guillain-Barré syndrome following the first dose of Pfizer-BioNTech COVID-19 vaccine: case report and review of reported cases 

COVID-19, Guillain-Barré syndrome, and the vaccine. A dangerous combination 

AstraZeneca COVID-19 vaccine and Guillain- Barré Syndrome in Tasmania: A causal link? 

Guillain-Barré syndrome following ChAdOx1 nCoV-19 COVID-19 vaccination: A case series 

Sensory Guillain-Barre syndrome following the ChAdOx1 nCov-19 vaccine: Report of two cases and review of literature 

A Novel Case of Bifacial Diplegia Variant of Guillain-Barré Syndrome Following Janssen COVID-19 Vaccination 

Guillian Barré syndromeafter mRNA-1273 vaccination against COVID-19 

SARS-CoV-2 vaccinations are unsafe for those experiencing post-vaccination Guillain-Barre syndrome 

Guillain-Barré syndrome following first injection of ChAdOx1 nCoV-19 vaccine: First report 

Guillain-Barré Syndrome Presenting as Facial Diplegia after COVID-19 Vaccination: A Case Report 

Guillain-Barré syndrome following the first dose of SARS-CoV-2 vaccine: A temporal occurrence, not a causal association 

Sensory Guillain-Barre syndrome following the ChAdOx1 nCov-19 vaccine: Report of two cases and review of literature 

Guillain-Barré syndrome after AstraZeneca COVID-19-vaccination: A causal or casual association? 

GM1 ganglioside antibody and COVID-19 related Guillain Barre Syndrome – A case report, systemic review and implication for vaccine development 

Exacerbation of Hailey-Hailey Disease Following SARS-CoV-2 Vaccination 

Recurrence of alopecia areata after covid-19 vaccination: A report of three cases in Italy 

A snapshot global survey on side effects of COVID-19 vaccines among healthcare professionals and armed forces with a focus on headache 

Headache Attributed to Vaccination Against COVID-19 (Coronavirus SARS-CoV-2) with the ChAdOx1 nCoV-19 (AZD1222) Vaccine: A Multicenter Observational Cohort Study 

The PULS Cardiac Test is a blood test that identifies people who are seemingly healthy, but who have a high risk of Heart Disease. The test detects the early stages of Heart Disease. by detecting the initial arterial or endothelial injury. leading to unstable cardiac lesion rupture

Abstract 10712: Observational Findings of PULS Cardiac Test Findings for Inflammatory Markers in Patients Receiving mRNA Vaccines 

Sudden sensorineural hearing loss after COVID-19 vaccination 

Hematuria is the presence of blood in a person’s urine. Gross hematuria is when a person can see the blood in his or her urine, and microscopic hematuria is when a person cannot see the blood in his or her urine, yet a health care professional can see it under a microscope.

Gross hematuria following vaccination for severe acute respiratory syndrome coronavirus 2 in 2 patients with IgA nephropathy 

Haematuria, a widespread petechial rash, and headaches following the Oxford AstraZeneca ChAdOx1 nCoV-19 Vaccination 

COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria 

Acral haemorrhage after the second dose administration of SARS-CoV-2 vaccine. A post-vaccinal reaction? 

Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: Large population-based cohort study 

Intracerebral haemorrhage twelve days after vaccination with ChAdOx1 nCoV-19 

Blood clots and bleeding events following BNT162b2 and ChAdOx1 nCoV-19 vaccine: An analysis of European data 

Henoch-Schonlein purpura (also known as IgA vasculitis) is a disorder that causes the small blood vessels in your skin, joints, intestines and kidneys to become inflamed and bleed. The most striking feature of this form of vasculitis is a purplish rash, typically on the lower legs and buttocks.

A Rare Case of Henoch-Schönlein Purpura Following a COVID-19 Vaccine—Case Report 

Hepatitis is a general term used to describe inflammation of the liver. Liver inflammation can be caused by several viruses (viral hepatitis), chemicals, drugs, alcohol, certain genetic disorders or by an overactive immune system that mistakenly attacks the liver, called autoimmune hepatitis.

Autoimmune hepatitis triggered by SARS-CoV-2 vaccination 

Immune-mediated hepatitis with the Moderna vaccine, no longer a coincidence but confirmed 

Autoimmune hepatitis developing after the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine 

Hepatitis C Virus Reactivation Following COVID-19 Vaccination – A Case Report 

Auto-immune hepatitis following COVID vaccination 

Acute autoimmune-like hepatitis with atypical anti-mitochondrial antibody after mRNA COVID-19 vaccination: A novel clinical entity? 

Any of a group of viral diseases caused by herpes viruses, affecting the skin (often with blisters) or the nervous system.

Recurrent herpes zoster after COVID-19 vaccination in patients with chronic urticaria being treated with cyclosporine—A report of 3 cases 

In genetics, the production of identical or similar phenotypes by different genetic mechanisms. A phenotype resembling a known phenotype but determined by a different genetic mechanism is called a genocopy or genetic mimic.

High Individual Heterogeneity of Neutralizing Activities against the Original Strain and Nine Different Variants of SARS-CoV-2 

SARS-CoV-2 mRNA Vaccine Attitudes as Expressed in U.S. FDA Public Commentary: Need for a Public-Private Partnership in a Learning Immunization System 

Acute lymphocytic leukemia (ALL) is a type of cancer of the blood and bone marrow.

Safety of administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG-asparaginase 

COVID 19 vaccine in patients of hypercoagulable disorders: a clinical perspective 

Minimal change disease and acute kidney injury following the Pfizer-BioNTech COVID-19 vaccine 

Nephrotic syndrome and vasculitis following SARS-CoV-2 vaccine: true association or circumstantial? 

Acute kidney injury with gross hematuria and IgA nephropathy after COVID-19 vaccination 

Minimal Change Disease With Severe Acute Kidney Injury Following the Oxford-AstraZeneca COVID-19 Vaccine: A Case Report 

Nephrotic Syndrome Following ChAdOx1 nCoV-19 Vaccine Against SARScoV-2 

Acute tubular necrosis is a condition that causes the lack of oxygen and blood flow to the kidneys, damaging them. Tube-shaped structures in the kidneys, called tubules, filter out waste products and fluid. These structures are damaged in acute tubular necrosis.

Acute Retinal Necrosis from Reactivation of Varicella Zoster Virus following BNT162b2 mRNA COVID-19 Vaccination 

Kounis syndrome is the concurrence of acute coronary syndromes with conditions associated with mast cell activation, such as allergies or hypersensitivity and anaphylactic or anaphylactoid insults that can involve other interrelated and interacting inflammatory cells behaving as a ‘ball of thread’.

Type 1 Kounis Syndrome Induced by Inactivated SARS-COV-2 Vaccine 

Acute Myocardial Infarction Within 24 Hours After COVID-19 Vaccination: Is Kounis Syndrome the Culprit? 

Blockage in the arteries of the lower extremities, which markedly reduces blood-flow. It is a serious form of peripheral arterial disease, or PAD, but less common than claudication.

Limb ischemia and pulmonary artery thrombosis after the ChAdOx1 nCoV-19 (Oxford–AstraZeneca) vaccine: a case of vaccine-induced immune thrombotic thrombocytopenia 

Autoimmune- and complement-mediated hematologic condition recrudescence following SARS-CoV-2 vaccination 

A lobar hemorrhage occurs when there is bleeding into a lobe of the cerebrum.

Lobar bleeding with ventricular rupture shortly after first dosage of an mRNA-based SARS-CoV-2 vaccine 

Longitudinally extensive transverse myelitis (LETM) is a neurological condition characterised by a contiguous inflammatory lesion of the spinal cord. LETM is often associated with the autoimmune central nervous system disease neuromyelitis optica (NMO) and rarely with multiple sclerosis.

Lessons of the month 1: Longitudinal extensive transverse myelitis following AstraZeneca COVID-19 vaccination 

Acute Eosinophilic Pneumonia Associated With the Anti-COVID-19 Vaccine AZD1222 

Cardiovascular, neurological, and pulmonary events following vaccination with the BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: An analysis of European data 

Induction and exacerbation of subacute cutaneous lupus erythematosus following mRNA-based or adenoviral vector-based SARS-CoV-2 vaccination 

 Lymphadenitis is the medical term for enlargement in one or more lymph nodes, usually due to infection. Lymph nodes are filled with white blood cells that help your body fight infections. When lymph nodes become infected, it’s usually because an infection started somewhere else in your body.

COVID-19 vaccine-related unilateral axillary lymphadenopathy: Pattern on screening breast MRI allowing for a benign assessment Michael J. Plaza Jervon Wright Sara Fernandez 

Massive Cervical Lymphadenopathy Post-COVID-19 Vaccination 

Evolution of Lymphadenopathy at PET/MRI after COVID-19 Vaccination 

Lymphadenopathy Associated With the COVID-19 Vaccine 

COVID-19 vaccination and low cervical lymphadenopathy in the two week neck lump clinic – a follow up audit 

Unilateral Lymphadenopathy After COVID-19 Vaccination: A Practical Management Plan for Radiologists Across Specialties 

A Case of Cervical Lymphadenopathy After Vaccination Against COVID-19 

Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F]Choline PET/CT—not only an FDG finding 

Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up using ultrasonography 

Unilateral axillary adenopathy induced by COVID-19 vaccine: US follow-up evaluation 

COVID-19 vaccine-related unilateral axillary lymphadenopathy: Pattern on screening breast MRI allowing for a benign assessment 

Massive Cervical Lymphadenopathy Post-COVID-19 Vaccination 

Evolution of Lymphadenopathy at PET/MRI after COVID-19 Vaccination 

Lymphadenopathy Associated With the COVID-19 Vaccine 

Cervical lymphadenopathy following coronavirus disease 2019 vaccine: clinical characteristics and implications for head and neck cancer services 

COVID-19 vaccination and low cervical lymphadenopathy in the two week neck lump clinic – a follow up audit 

COVID-19 Vaccine-Related Axillary and Cervical Lymphadenopathy in Patients with Current or Prior Breast Cancer and Other Malignancies: Cross-Sectional Imaging Findings on MRI, CT, and PET-CT 

Supraclavicular lymphadenopathy following COVID-19 vaccination: an increasing presentation to the two-week wait neck lump clinic? 

Unilateral Lymphadenopathy After COVID-19 Vaccination: A Practical Management Plan for Radiologists Across Specialties 

A Case of Cervical Lymphadenopathy After Vaccination Against COVID-19 

Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F]Choline PET/CT—not only an FDG finding 

Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up using ultrasonography  

Acute onset supraclavicular lymphadenopathy coinciding with intramuscular mRNA vaccination against COVID-19 may be related to vaccine injection technique, Spain, January and February 2021 

COVID-19 Vaccine-Associated Subclinical Axillary Lymphadenopathy on Screening Mammogram 

Regional lymphadenopathy following COVID-19 vaccination: Literature review and considerations for patient management in breast cancer care 

COVID-19 post-vaccination lymphadenopathy: Report of cytological findings from fine needle aspiration biopsy 

COVID-19 Vaccination Induced Lymphadenopathy in a Specialized Breast Imaging Clinic in Israel: Analysis of 163 cases 

COVID-19 Vaccination–Associated Lymphadenopathy on FDG PET/CT 

Evolving Bilateral Hypermetabolic Axillary Lymphadenopathy on FDG PET/CT Following 2-Dose COVID-19 Vaccination 

Lymphadenopathy Following COVID-19 Vaccination: Imaging Findings Review 

Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [18F]FDG PET-CT and relevance to study interpretation 

COVID-19 mRNA Vaccination–Induced Lymphadenopathy Mimics Lymphoma Progression on FDG PET/CT 

Rare case of contralateral supraclavicular lymphadenopathy after COVID-19 vaccination: Computed tomography and ultrasonography findings 

Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up using ultrasonography 

COVID-19 vaccine induced Axillary and Pectoral Lymphadenopathy on PET scan 

Hemophagocytic lymphohistiocytosis following ChAdOx1 nCov-19 vaccination 

Rituximab-induced acute lympholysis and pancytopenia after COVID-19 vaccination 

Response to Letter to the editors referring to Fikenzer, S., Uhe, T., Lavall, D., Rudolph, U., Falz, R., Busse, M., Hepp, P., & Laufs, U. (2020). Effects of surgical and FFP2/N95 face masks on cardiopulmonary exercise capacity. Clinical research in cardiology: official journal of the German Cardiac Society, 1–9. Advance online publication. 

Miller Fisher syndrome is a rare, acquired nerve disease that is considered to be a variant of Guillain-Barré syndrome. It is characterized by abnormal muscle coordination, paralysis of the eye muscles, and absence of the tendon reflexes.

Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination 

Miller Fisher syndrome following Pfizer COVID-19 vaccine 

Acute Hemichorea-Hemiballismus Following COVID-19 (AZD1222) Vaccination 

Severe Multiple Sclerosis Relapse After COVID-19 Vaccination: A Case Report 

Acute relapse and poor immunization following COVID-19 vaccination in a rituximab-treated multiple sclerosis patient 

MIS is a rare but serious condition associated with COVID-19 in which different body parts become inflamed, including the heart, lungs, kidneys, brain, skin, eyes, or gastrointestinal organs.

Multisystem inflammatory syndrome in a male adolescent after his second Pfizer-BioNTech COVID-19 vaccine 

Autoantibody Release in Children after Corona Virus mRNA Vaccination: A Risk Factor of Multisystem Inflammatory Syndrome? 

Postvaccination Multisystem Inflammatory Syndrome in Adult with No Evidence of Prior SARS-CoV-2 Infection 

Inflammation of the spinal cord.

Lessons of the month 1: Longitudinal extensive transverse myelitis following AstraZeneca COVID-19 vaccination 

Post COVID-19 transverse myelitis; a case report with review of literature 

A case of longitudinally extensive transverse myelitis following vaccination against Covid-19 

Acute Transverse Myelitis Following COVID-19 Vaccination 

Acute transverse myelitis after inactivated COVID-19 vaccine 

Acute transverse myelitis following SARS-CoV-2 vaccination: a case report and review of literature 

Cervical longitudinally extensive myelitis after vaccination with inactivated virus-based COVID-19 vaccine 

Longitudinal extensive transverse myelitis following ChAdOx1 nCOV-19 vaccine: a case report 

SARS-CoV-2 Vaccination-Induced Transverse Myelitis 

Acute Transverse Myelitis (ATM):Clinical Review of 43 Patients With COVID-19-Associated ATM and 3 Post-Vaccination ATM Serious Adverse Events With the ChAdOx1 nCoV-19 Vaccine (AZD1222) 

Acute myelitis and ChAdOx1 nCoV-19 vaccine: Casual or causal association? 

Rituximab-induced acute lympholysis and pancytopenia after COVID-19 vaccination 

Acute Transverse Myelitis after COVID-19 Vaccination 

Acute Transverse Myelitis (ATM):Clinical Review of 43 Patients With COVID-19-Associated ATM and 3 Post-Vaccination ATM Serious Adverse Events With the ChAdOx1 nCoV-19 Vaccine (AZD1222) 

Untimely Myocardial Infarction or COVID-19 Vaccine Side Effect 

Acute myocardial infarction and myocarditis following COVID-19 vaccination 

Myocardial Infarction and Azygos Vein Thrombosis After ChAdOx1 nCoV-19 Vaccination in a Hemodialysis Patient 

Acute Myocardial Infarction Within 24 Hours After COVID-19 Vaccination 

A rare condition in which the heart muscle becomes thick and inflamed and may also become weak.

Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections 

Myocarditis after BNT162b2 vaccination in a healthy male 

Myocarditis Following mRNA COVID-19 Vaccine 

Myocarditis and Other Cardiovascular Complications of the mRNA-Based COVID-19 Vaccines 

Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults: Suspected Myocarditis After COVID-19 Vaccination 

Eosinophilic Myocarditis Following Coronavirus Disease 2019 (COVID-19) Vaccination 

Case report: acute myocarditis following the second dose of mRNA-1273 SARS-CoV-2 vaccine 

Temporal Association Between the COVID-19 Ad26.COV2.S Vaccine and Acute Myocarditis: A Case Report and Literature Review 

Myocarditis Associated with mRNA COVID-19 Vaccination 

Risk of Myocarditis from COVID-19 Infection in People Under Age 20: A Population-Based Analysis 

Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older 

Myocarditis following COVID-19 vaccination: magnetic resonance imaging study 

Cardiac MRI Assessment of Nonischemic Myocardial Inflammation: State of the Art Review and Update on Myocarditis Associated with COVID-19 Vaccination 

Myocarditis Following Coronavirus Disease 2019 mRNA Vaccine: A Case Series and Incidence Rate Determination 

Acute myocarditis following Comirnaty vaccination in a healthy man with previous SARS-CoV-2 infection 

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection 

Cardiovascular magnetic resonance findings in young adult patients with acute myocarditis following mRNA COVID-19 vaccination: a case series 

Self-limited myocarditis presenting with chest pain and ST segment elevation in adolescents after vaccination with the BNT162b2 mRNA vaccine 

Epidemiology and Clinical Features of Myocarditis/Pericarditis before the Introduction of mRNA COVID-19 Vaccine in Korean Children: a Multicenter Study 

Acute myocarditis associated with COVID-19 vaccination: A case report 

Myocarditis Following a COVID-19 Messenger RNA Vaccination: A Japanese Case Series 

Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military 

Recurrence of Acute Myocarditis Temporally Associated with Receipt of the mRNA Coronavirus Disease 2019 (COVID-19) Vaccine in a Male Adolescent 

Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel 

Myocarditis and Pericarditis After COVID-19 mRNA Vaccination: Practical Considerations for Care Providers 

Case Report: Acute Fulminant Myocarditis and Cardiogenic Shock After Messenger RNA Coronavirus Disease 2019 Vaccination Requiring Extracorporeal Cardiopulmonary Resuscitation

Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types 

Myocarditis following COVID-19 vaccination – A case series 

Reply to ‘Letter to the editor: Myocarditis should be considered in those with a troponin rise and unobstructed coronary arteries following PfizerBioNTech COVID-19 vaccination’ 

mRNA COVID vaccine and myocarditis in adolescents 

Myocarditis following mRNA vaccination against SARS-CoV-2, a case series 

Cardiac Imaging of Acute Myocarditis Following COVID-19 mRNA Vaccination 

Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination 

Myocarditis following COVID-19 vaccination 

Young Male With Myocarditis Following mRNA-1273 Vaccination Against Coronavirus Disease-2019 (COVID-19) 

Myocarditis and pericarditis in association with COVID-19 mRNA-vaccination: cases from a regional pharmacovigilance centre 

Myocarditis Following COVID-19 Vaccination 

T2 mapping should be utilized in cases of suspected myocarditis to confirm an acute inflammatory process 

Myocarditis should be considered in those with a troponin rise and unobstructed coronary arteries following Pfizer-BioNTech COVID-19 vaccination 

A review of COVID-19 vaccination and the reported cardiac manifestations 

The very low risk of myocarditis and pericarditis after mRNA COVID-19 vaccination should not discourage vaccination 

Myocarditis after vaccination against covid-19 

A Late Presentation of COVID-19 Vaccine-Induced Myocarditis 

Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021 

Myocarditis and pericarditis in adolescents after first and second doses of mRNA COVID-19 vaccines 

Cardiac complications following mRNA COVID-19 vaccines: A systematic review of case reports and case series 

Miocardite acuta in giovane adulto due giorni dopo vaccino Pfizer 

A Series of Patients With Myocarditis Following SARS-CoV-2 Vaccination With mRNA-1279 and BNT162b2 

Acute Myocardial Injury Following COVID-19 Vaccination: A Case Report and Review of Current Evidence from Vaccine Adverse Events Reporting System Database 

Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination: What Do We Know So Far? 

Should T2 mapping be used in cases of recurrent myocarditis to differentiate between the acute inflammation and chronic scar? 

Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination 

Features of Inflammatory Heart Reactions Following mRNA COVID-19 Vaccination at a Global Level 

Cardiac MRI Findings of Myocarditis After COVID-19 mRNA Vaccination in Adolescents Read More: https://www.ajronline.org/doi/10.2214/AJR.21.26853 

Occurrence of acute infarct-like myocarditis following COVID-19 vaccination: just an accidental co-incidence or rather vaccination-associated autoimmune myocarditis? 

COVID 19 Vaccine for Adolescents. Concern about Myocarditis and Pericarditis 

Myocarditis With COVID-19 mRNA Vaccines 

Coronavirus and cardiovascular manifestations- getting to the heart of the matter 

STEMI Mimic: Focal Myocarditis in an Adolescent Patient After mRNA COVID-19 Vaccine 

Acute myocardial infarction and myocarditis following COVID-19 vaccination 

Myocarditis following COVID-19 vaccination 

Myocarditis following COVID-19 mRNA vaccination 

Fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 mRNA COVID-19 vaccination in two patients 

Acute Myocardial Infarction Within 24 Hours After COVID-19 Vaccination: Is Kounis Syndrome the Culprit? 

Epidemiology of myocarditis and pericarditis following mRNA vaccines in Ontario, Canada: by vaccine product, schedule and interval 

Myocarditis following mRNA vaccination against SARS-CoV-2, a case series 

Myocarditis after Covid-19 Vaccination in a Large Health Care Organization 

Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults: Suspected Myocarditis After COVID-19 Vaccination 

Association of Myocarditis With BNT162b2 Messenger RNA COVID-19 Vaccine in a Case Series of Children 

Myocarditis following COVID-19 vaccination: magnetic resonance imaging study 

Biventricular systolic dysfunction in acute myocarditis after SARS-CoV-2 mRNA-1273 vaccination 

Definite Acute Myocarditis After Coronavirus Disease 2019 mRNA Vaccination 

A Series of Patients With Myocarditis Following SARS-CoV-2 Vaccination With mRNA-1279 and BNT162b2 

The Anatolian Journal of Cardiology 

Case Report: Acute Fulminant Myocarditis and Cardiogenic Shock After Messenger RNA Coronavirus Disease 2019 Vaccination Requiring Extracorporeal Cardiopulmonary Resuscitation

Miocardite acuta in giovane adulto due giorni dopo vaccino Pfizer 

Acute myocarditis following Comirnaty vaccination in a healthy man with previous SARS-CoV-2 infection  

Biopsy-proven lymphocytic myocarditis following first mRNA COVID-19 vaccination in a 40-year-old male: case report 

Multimodality imaging and histopathology in a young man presenting with fulminant lymphocytic myocarditis and cardiogenic shock after mRNA-1273 vaccination 

Chest Pain with New Abnormal Electrocardiogram Development after Injection of COVID-19 Vaccine Manufactured by Moderna 

Acute Myocarditis Following mRNA-1273 SARS-CoV-2 Vaccination 

Myocarditis after BNT162b2 vaccination in a healthy male 

Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military 

Self-limited myocarditis presenting with chest pain and ST segment elevation in adolescents after vaccination with the BNT162b2 mRNA vaccine 

Occurrence of acute infarct-like myocarditis following COVID-19 vaccination: just an accidental co-incidence or rather vaccination-associated autoimmune myocarditis? 

68Ga-DOTATOC digital-PET imaging of inflammatory cell infiltrates in myocarditis following COVID-19 vaccination 

Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old man 

Young Male With Myocarditis Following mRNA-1273 Vaccination Against Coronavirus Disease-2019 (COVID-19) 

Recurrence of Acute Myocarditis Temporally Associated with Receipt of the mRNA Coronavirus Disease 2019 (COVID-19) Vaccine in a Male Adolescent 

Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older 

Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination 

Cardiovascular magnetic resonance findings in young adult patients with acute myocarditis following mRNA COVID-19 vaccination: a case series 

Myocarditis associated with COVID‑19 vaccination in three male teenagers 

Shedding the Light on Post-Vaccine Myocarditis and Pericarditis in COVID-19 and Non-COVID-19 Vaccine Recipients 

Epidemiology and Clinical Features of Myocarditis/Pericarditis before the Introduction of mRNA COVID-19 Vaccine in Korean Children: a Multicenter Study 

Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types 

Myocarditis Following Coronavirus Disease 2019 mRNA Vaccine: A Case Series and Incidence Rate Determination 

Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination 

Acute myocarditis after a second dose of the mRNA COVID-19 vaccine: a report of two cases 

Myocarditis in the Setting of Recent COVID-19 Vaccination 

Myocarditis Following a COVID-19 Messenger RNA Vaccination: A Japanese Case Series 

Acute myocarditis associated with COVID-19 vaccination: A case report 

Acute Myocardial Injury Following COVID-19 Vaccination: A Case Report and Review of Current Evidence from Vaccine Adverse Events Reporting System Database 

Myocarditis Temporally Associated With COVID-19 Vaccination 

Cardiac Imaging of Acute Myocarditis Following COVID-19 mRNA Vaccination 

COVID 19 Vaccine for Adolescents. Concern about Myocarditis and Pericarditis 

Symptomatic Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination 

Myocarditis Associated With COVID-19 Vaccination 

Acute myocarditis associated with anti-COVID-19 vaccination 

Acute Myocarditis after COVID-19 vaccination: A case report 

Myocarditis Associated with mRNA COVID-19 Vaccination 

Acute myocarditis after administration of the BNT162b2 vaccine against COVID-19 

Case Report: Probable Myocarditis After Covid-19 mRNA Vaccine in a Patient With Arrhythmogenic Left Ventricular Cardiomyopathy 

Cardiac MRI Findings of Myocarditis After COVID-19 mRNA Vaccination in Adolescents

COVID-19 Vaccination–Associated Myocarditis in Adolescents 

Myocarditis following COVID-19 vaccination – A case series 

Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination 

Myocarditis after COVID-19 mRNA vaccines 

Myocarditis and pericarditis in association with COVID-19 mRNA-vaccination: cases from a regional pharmacovigilance centre 

STEMI Mimic: Focal Myocarditis in an Adolescent Patient After mRNA COVID-19 Vaccine 

Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults: Suspected Myocarditis After COVID-19 Vaccination

Association of Myocarditis With BNT162b2 Messenger RNA COVID-19 Vaccine in a Case Series of Children 

Myocarditis after Covid-19 Vaccination in a Large Health Care Organization 

Acute myocardial infarction and myocarditis following COVID-19 vaccination 

Severe COVID-19 vaccine associated myocarditis: Zebra or unicorn? 

Possible Association Between COVID-19 Vaccine and Myocarditis: Clinical and CMR Findings 

Myocarditis and Other Cardiovascular Complications of the mRNA-Based COVID-19 Vaccines 

Myocarditis, Pericarditis and Cardiomyopathy After COVID-19 Vaccination 

Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel 

Myocarditis Following mRNA COVID-19 Vaccine 

Shedding the Light on Post-Vaccine Myocarditis and Pericarditis in COVID-19 and Non-COVID-19 Vaccine Recipients 

Epidemiology and Clinical Features of Myocarditis/Pericarditis before the Introduction of mRNA COVID-19 Vaccine in Korean Children: a Multicenter Study 

Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types 

Myocarditis Following Coronavirus Disease 2019 mRNA Vaccine: A Case Series and Incidence Rate Determination 

Lymphohistocytic myocarditis after Ad26.COV2.S viral vector COVID-19 vaccination 

Fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 mRNA COVID-19 vaccination in two patients 

Case report: acute myocarditis following the second dose of mRNA-1273 SARS-CoV-2 vaccine 

Myocarditis and Other Cardiovascular Complications of the mRNA-Based COVID-19 Vaccines 

Acute myocarditis after administration of the BNT162b2 vaccine against COVID-19  

Biopsy-proven lymphocytic myocarditis following first mRNA COVID-19 vaccination in a 40-year-old male: case report 

Self-limited myocarditis presenting with chest pain and ST segment elevation in adolescents after vaccination with the BNT162b2 mRNA vaccine 

Myocarditis After SARS-CoV-2 Vaccination: A Vaccine-Induced Reaction? 

Recurrence of Acute Myocarditis Temporally Associated with Receipt of the mRNA Coronavirus Disease 2019 (COVID-19) Vaccine in a Male Adolescent  

Occurrence of acute infarct-like myocarditis following COVID-19 vaccination: just an accidental co-incidence or rather vaccination-associated autoimmune myocarditis? 

In-Depth Evaluation of a Case of Presumed Myocarditis After the Second Dose of COVID-19 mRNA Vaccine 

Myocarditis Associated With COVID-19 Vaccination 

Acute Myocardial Injury Following COVID-19 Vaccination: A Case Report and Review of Current Evidence from Vaccine Adverse Events Reporting System Database 

The Novel Platform of mRNA COVID-19 Vaccines and Myocarditis: Clues into the Potential Underlying Mechanism 

COVID-19 vaccine-associated myocarditis/pericarditis 

Case report: acute myocarditis following the second dose of mRNA-1273 SARS-CoV-2 vaccine 

Cardiac Imaging of Acute Myocarditis Following COVID-19 mRNA Vaccination 

Clinical guidance for youth with myocarditis and pericarditis following mRNA COVID-19 Vaccination 

Cardiovascular magnetic resonance findings in young adult patients with acute myocarditis following mRNA COVID-19 vaccination: a case series 

Symptomatic Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination 

Myocarditis Associated with mRNA COVID-19 Vaccination 

Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination 

Myocarditis after Covid-19 mRNA Vaccination 

Myocarditis Occurring After Immunization With mRNA-Based COVID-19 Vaccines 

Association of Myocarditis With BNT162b2 Messenger RNA COVID-19 Vaccine in a Case Series of Children 

Myocarditis With COVID-19 mRNA Vaccines 

Myocarditis, Pericarditis and Cardiomyopathy After COVID-19 Vaccination 

Myocarditis and Other Cardiovascular Complications of the mRNA-Based COVID-19 Vaccines 

COVID-19 vaccines and myocarditis 

COVID-19 Vaccine and Myocarditis 

COVID-19 mRNA Vaccine and Myocarditis 

A Series of Patients With Myocarditis Following SARS-CoV-2 Vaccination With mRNA-1279 and BNT162b2 

Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old man 

Temporal relation between second dose BNT162b2 mRNA Covid-19 vaccine and cardiac involvement in a patient with previous SARS-COV-2 infection 

Acute Myocarditis Following mRNA-1273 SARS-CoV-2 Vaccination 

Acute myocarditis following Comirnaty vaccination in a healthy man with previous SARS-CoV-2 infection 

Myocarditis after BNT162b2 vaccination in a healthy male 

Lymphohistocytic myocarditis after Ad26.COV2.S viral vector COVID-19 vaccination 

Acute myocarditis following administration of BNT162b2 vaccine 

Fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 mRNA COVID-19 vaccination in two patients 

Recurrence of Acute Myocarditis Temporally Associated with Receipt of the mRNA Coronavirus Disease 2019 (COVID-19) Vaccine in a Male Adolescent 

A rare condition in which the heart muscle becomes thick and inflamed and may also become weak.

Myopericarditis After the Pfizer Messenger Ribonucleic Acid Coronavirus Disease Vaccine in Adolescents 

Population-based Incidence of Myopericarditis After COVID-19 Vaccination in Danish Adolescents 

Myopericarditis in a previously healthy adolescent male following COVID-19 vaccination: A case report 

Important Insights into Myopericarditis after the Pfizer mRNA COVID-19 Vaccination in Adolescents 

mRNA Coronavirus Disease 2019 Vaccine-Associated Myopericarditis in Adolescents: A Survey Study 

Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase 

Biopsy-proven lymphocytic myocarditis following first mRNA COVID-19 vaccination in a 40-year-old male: case report 

Myopericarditis after messenger RNA Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of Age 

Acute Myopericarditis after COVID-19 Vaccine in Teenagers 

Myopericarditis After the Pfizer Messenger Ribonucleic Acid Coronavirus Disease Vaccine in Adolescents 

A Case Report for Myopericarditis after BNT162b2 COVID-19 mRNA Vaccination in a Korean Young Male 

Myopericarditis in a previously healthy adolescent male following COVID-19 vaccination: A case report 

Myositis is an inflammation or swelling of the muscles. It is most often caused by injury, infection, medicines, or an autoimmune disorder.

Inflammatory myositis after ChAdOx1 vaccination 

Nephrotic syndrome is a group of symptoms that indicate your kidneys are not working properly. These symptoms include. too much protein in your urine, called proteinuria. low levels of a protein called albumin in your blood, called hypoalbuminemia. swelling in parts of your body, called edema.

New-onset Nephrotic Syndrome after Janssen COVID-19 Vaccination: a Case Report and Literature Review 

Nephropathy is a medical term for kidney disease. The type of kidney disease caused by diabetes is called diabetic nephropathy.

A case of gross hematuria and IgA nephropathy flare-up following SARS-CoV-2 vaccination 

An inflammatory or degenerative lesion of a nerve marked especially by pain, sensory disturbances, and impaired or lost reflexes.

Acute bilateral optic/chiasm neuritis with longitudinal extensive transverse myelitis in longstanding stable multiple sclerosis following vector-based vaccination against the SARS-CoV-2 

Qualitative olfactory dysfunctions, such as parosmia and phantosmia, may be clinical conditions secondary to neurological diseases. The incidence of parosmia is underestimated, as well as its association with neurological diseases, due to poor self-reporting of patients and lack of objective methods for its measure.

Unique Imaging Findings of Neurologic Phantosmia Following Pfizer-BioNtech COVID-19 Vaccination: A Case Report 

Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection 

Hospital-based observational study of neurological disorders in patients recently vaccinated with COVID-19 mRNA vaccines 

Spectrum of neurological complications following COVID-19 vaccination 

Neurological symptoms and neuroimaging alterations related with COVID-19 vaccine: Cause or coincidence? 

SARS-CoV-2 or SARS-CoV-2 vaccination associated Parsonage-Turner syndrome. Comment on: “Neuralgic amyotrophy and COVID-19 infection: 2 cases of spinal accessory nerve palsy” by Coll et al. Joint Bone Spine 2021;88:105196 

A nerve problem that causes pain, numbness, tingling, swelling, or muscle weakness in different parts of the body. It usually begins in the hands or feet and gets worse over time.

Reporting of Acute Inflammatory Neuropathies with COVID-19 Vaccines: Subgroup Disproportionality Analyses in VigiBase 

Neuromyelitis optica (NMO), also known as Devic’s disease, is a rare condition where the immune system damages the spinal cord and the nerves of the eyes (optic nerves). NMO can affect anyone at any age, but it’s more common in women than men.

Neuromyelitis Optica in a Healthy Female After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccine 

Watch out for neuromyelitis optica spectrum disorder after inactivated virus vaccination for COVID-19 

Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination 

New-onset refractory status epilepticus following the ChAdOx1 nCoV-19 vaccine 

New-onset refractory status epilepticus following the ChAdOx1 nCoV-19 vaccine 

Neurological side effects of SARS-CoV-2 vaccinations 

Spectrum of Neuroimaging Findings in Post-COVID-19 Vaccination: A Case Series and Review of Literature 

Neurological symptoms and neuroimaging alterations related with COVID-19 vaccine: Cause or coincidence? 

Nervous and Muscular Adverse Events after COVID-19 Vaccination: A Systematic Review and Meta-Analysis of Clinical Trials 

Pancreas allograft rejection occurring after ChAdOx1 nCoV-19 vaccine 

Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines 

Myocarditis and Pericarditis After COVID-19 mRNA Vaccination: Practical Considerations for Care Providers 

Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types 

The very low risk of myocarditis and pericarditis after mRNA COVID-19 vaccination should not discourage vaccination 

Myocarditis and pericarditis in adolescents after first and second doses of mRNA COVID-19 vaccines 

Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination: What Do We Know So Far? 

A case report: symptomatic pericarditis post-COVID-19 vaccination 

Pericarditis after administration of the BNT162b2 mRNA COVID-19 vaccine 

Myocarditis and pericarditis in adolescents after first and second doses of mRNA COVID-19 vaccines 

Acute pericarditis and cardiac tamponade after Covid-19 vaccination 

A case series of acute pericarditis following COVID-19 vaccination in the context of recent reports from Europe and the United States 

Pericarditis after administration of the BNT162b2 mRNA COVID-19 vaccine 

Perimyocarditis is an acute inflammation of the pericardium and the underlying myocardium resulting in myocellular damage. It is usually asymptomatic with complete resolution in most cases. It can however lead to fulminant cardiac failure resulting in death or requiring cardiac transplantation.

Perimyocarditis Following COVID-19 Vaccination 

Transient Cardiac Injury in Adolescents Receiving the BNT162b2 mRNA COVID-19 Vaccine 

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection 

Unusual Presentation of Acute Perimyocarditis Following SARS-COV-2 mRNA-1237 Moderna Vaccination 

Weighing the Risks of Perimyocarditis With the Benefits of SARS-CoV-2 mRNA Vaccination in Adolescents 

Perimyocarditis following first dose of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine in a healthy young male: a case report 

Perimyocarditis in Adolescents After Pfizer-BioNTech COVID-19 Vaccine 

Perimyocarditis Following COVID-19 Vaccination 

Perimyocarditis in Adolescents After Pfizer-BioNTech COVID-19 Vaccine 

Acute Myopericarditis after COVID-19 Vaccine in Teenagers 

Acute Perimyocarditis Following First Dose of mRNA Vaccine Against COVID-19 

Transient Cardiac Injury in Adolescents Receiving the BNT162b2 mRNA COVID-19 Vaccine 

Unusual Presentation of Acute Perimyocarditis Following SARS-COV-2 mRNA-1237 Moderna Vaccination 

Perimyocarditis in Adolescents After Pfizer-BioNTech COVID-19 Vaccine 

Transient Cardiac Injury in Adolescents Receiving the BNT162b2 mRNA COVID-19 Vaccine 

An olfactory hallucination (phantosmia) makes you detect smells that aren’t really present in your environment. The odors detected in phantosmia vary from person to person and may be foul or pleasant. They can occur in one or both nostrils. 

Unique Imaging Findings of Neurologic Phantosmia Following Pfizer-BioNtech COVID-19 Vaccination: A Case Report 

An inflammatory disease of small arteries and veins (vasculitis) that classically involves vessels supplying the tissues of the lungs, nasal passages (sinuses), and kidneys.

Relapse of microscopic polyangiitis after vaccination against COVID-19: A case report 

A medical condition where pain occurs in several joints of the body.

Polyarthralgia and Myalgia Syndrome after ChAdOx1 nCOV-19 Vaccination 

BNT162b2 Vaccination during Pregnancy Protects Both the Mother and Infant: Anti-SARS-CoV-2 S Antibodies Persistently Positive in an Infant at 6 Months of Age 

Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons 

Onset/flare of psoriasis following the ChAdOx1 nCoV-19 Corona virus vaccine (Oxford-AstraZeneca/Covishield): Report of two cases 

Pulmonary embolism (PE) occurs when a blood clot gets stuck in an artery in the lung, blocking blood flow to part of the lung. Blood clots most often start in the legs and travel up through the right side of the heart and into the lungs. This is called deep vein thrombosis (DVT).

Myocardial Infarction, Stroke, and Pulmonary Embolism After BNT162b2 mRNA COVID-19 Vaccine in People Aged 75 Years or Older 

Isolated pulmonary embolism following COVID vaccination: 2 case reports and a review of post-acute pulmonary embolism complications and follow-up 

Pulmonary embolism, transient ischaemic attack and thrombocytopenia after the Johnson & Johnson COVID-19 vaccine 

A Case of Acute Pulmonary Embolus after mRNA SARS-CoV-2 Immunization 

COVID-19 vaccine-associated acute cerebral venous thrombosis and pulmonary artery embolism 

Pulmonary embolism, transient ischaemic attack and thrombocytopenia after the Johnson & Johnson COVID-19 vaccine 

A 59-Year-Old Woman with Extensive Deep Vein Thrombosis and Pulmonary Thromboembolism 7 Days Following a First Dose of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine   

COVID-19 vaccine-associated acute cerebral venous thrombosis and pulmonary artery embolism 

Purpura annularis telangiectodes is a pigmented, purpuric eruption that occurs most commonly in adolescents and young adults. The disease is characterized by symmetrical, purpuric, telangiectatic, and atrophic patches, with a predilection for the lower extremities and buttocks.

Widespread purpura annularis telangiectodes following mRNA SARS-CoV-2 vaccine 

Recurrence of Myopericarditis Following mRNA COVID-19 Vaccination in a Male Adolescent 

Retinal Hemorrhage after SARS-CoV-2 Vaccination 

COVID-19 mRNA vaccine induced rhabdomyolysis and fasciitis 

COVID-19 vaccine induced rhabdomyolysis: Case report with literature review 

COVID-19 vaccine induced rhabdomyolysis: Case report with literature review 

Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis 

Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study 

Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 

COVID-19 Vaccine Safety in Adolescents Aged 12–17 Years — United States, December 14, 2020–July 16, 2021 

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study 

Immunogenicity of the COVID-19 mRNA vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors 

Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting 

Pfizer’s vaccine raises allergy concerns 

Process-related impurities in the ChAdOx1 nCov-19 vaccine 

An academic hospital experience screening mRNA COVID-19 vaccine risk using patient allergy history 

Be Alert to the Risk of Adverse Cardiovascular Events after COVID-19 Vaccination 

Prevalence of severe adverse events among health professionals after receiving the first dose of the ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021

Clinical and histopathological spectrum of delayed adverse cutaneous reactions following COVID-19 vaccination 

Increased Risk of Urticaria/Angioedema after BNT162b2 mRNA COVID-19 Vaccine in Health Care Workers Taking ACE Inhibitors 

Eosinophilic dermatosis after AstraZeneca COVID-19 vaccination 

Cutaneous adverse reactions from 35,229 doses of Sinovac and AstraZeneca COVID-19 vaccination: a prospective cohort study in healthcare workers 

A case of toxic epidermal necrolysis after ChAdOx1 nCov-19 (AZD1222) vaccination 

Herpes-like skin lesion after AstraZeneca vaccination for COVID-19: A case report 

Case Report: Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination 

Petechial skin rash associated with CoronaVac vaccination: first cutaneous side effect report before phase 3 results 

Rare cutaneous adverse effects of COVID-19 vaccines: a case series and review of the literature 

Generalized bullous fixed drug eruption after Oxford–AstraZeneca (ChAdOx1 nCoV-19) vaccination 

Bilateral Immune-Mediated Keratolysis After Immunization With SARS-CoV-2 Recombinant Viral Vector Vaccine 

Petechiae and Desquamation of Fingers Following Immunization With BTN162b2 Messenger RNA (mRNA) COVID-19 Vaccine 

Cutaneous thrombosis associated with skin necrosis following Oxford-AstraZeneca COVID-19 vaccination 

Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases  

Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: A registry-based study 

Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases 

Cutaneous adverse effects of the available COVID-19 vaccines 

Bullous drug eruption after second dose of mRNA-1273 (Moderna) COVID-19 vaccine: Case report 

Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: A registry-based study 

Delayed cutaneous reactions after the administration of mRNA vaccines against COVID-19 

Purpuric Rash and Thrombocytopenia After the mRNA-1273 (Moderna) COVID-19 Vaccine 

Spectrum of Suspected Cardiomyopathy Due to COVID-19: A Case Series 

Post-COVID-19 vaccination occurrence of splenic infarction due to arterial thrombosis 

Socio-economic inequalities and COVID-19 incidence and mortality in Brazilian children: a nationwide register-based study 

Analysis of Staphylococcus aureus Transcriptome in Pediatric Soft Tissue Abscesses and Comparison to Murine Infections 

A flare of Still’s disease following COVID-19 vaccination in a 34-year-old patient 

Acute Ischaemic Stroke Incidence after Coronavirus Vaccine in Indonesia: Case Series 

Bilateral Thalamic Stroke: A Case of COVID-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) or a Coincidence Due to Underlying Risk Factors? 

Large hemorrhagic stroke after ChAdOx1 nCoV-19 vaccination: A case report 

Ischaemic stroke as a presenting feature of ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia  

Large hemorrhagic stroke after ChAdOx1 nCoV-19 vaccination: A case report 

Thrombocytopenia with acute ischemic stroke and bleeding in a patient newly vaccinated with an adenoviral vector-based COVID-19 vaccine 

Acute Ischemic Stroke Revealing ChAdOx1 nCov-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia: Impact on Recanalization Strategy 

Malignant cerebral infarction after ChAdOx1 nCov-19 vaccination: a catastrophic variant of vaccine-induced immune thrombotic thrombocytopenia 

A case of generalized Sweet syndrome with vasculitis triggered by recent COVID-19 vaccination 

Sweet syndrome after Oxford-AstraZeneca COVID-19 vaccine (AZD1222) in an elderly female 

Systemic capillary leak syndrome after ChAdOx1 nCOV-19 (Oxford–AstraZeneca) vaccination 

Takotsubo cardiomyopathy after vaccination for coronavirus disease 2019 in a patient on maintenance hemodialysis 

Takotsubo syndrome after receiving the COVID-19 vaccine 

Takotsubo (stress) cardiomyopathy after ChAdOx1 nCoV-19 vaccination 

Takotsubo Cardiomyopathy After mRNA COVID-19 Vaccination 

Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine 

Robust T-Cell Responses in Anti-CD20-Treated Patients Following COVID-19 Vaccination: A Prospective Cohort Study 

Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS) 

Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine — United States, March–April 2021 

Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination 

Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study 

Severe, Refractory Immune Thrombocytopenia Occurring After SARS-CoV-2 Vaccine 

Vaccine-Associated Thrombocytopenia and Thrombosis: Venous Endotheliopathy Leading to Venous Combined Micro-Macrothrombosis 

SEVERE IMMUNE THROMBOCYTOPENIC PURPURA AFTER SARS-COV-2 VACCINE 

Symptomatic peduncular, cavernous bleeding following SARS-CoV-2 vaccination induced immune thrombocytopenia 

Immune thrombocytopenia relapse post covid-19 vaccine in young male patient 

Vaccine-induced thrombotic thrombocytopenia following Ad26.COV2.S vaccine in a man presenting as acute venous thromboembolism 

Case Report: Vaccine-Induced Immune Thrombotic Thrombocytopenia in a Pancreatic Cancer Patient After Vaccination With Messenger RNA−1273

Successful Treatment of Vaccine-Induced Immune Thrombotic Thrombocytopenia in a 26-Year-Old Female Patient 

Thrombocytopenia and splanchnic thrombosis after Ad26.COV2.S vaccination successfully treated with transjugular intrahepatic portosystemic shunting and thrombectomy 

Management of a patient with a rare congenital limb malformation syndrome after SARS-CoV-2 vaccine-induced thrombosis and thrombocytopenia (VITT) 

Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia 

Case Report: Take a Second Look: Covid-19 Vaccination-Related Cerebral Venous Thrombosis and Thrombotic Thrombocytopenia Syndrome 

Inflammation and Platelet Activation After COVID-19 Vaccines – Possible Mechanisms Behind Vaccine-Induced Immune Thrombocytopenia and Thrombosis 

Prevalence of thrombocytopenia, anti–platelet factor 4 antibodies and D-dimer elevation in Thai people After ChAdOx1 nCoV-19 vaccination 

Complicated Long Term Vaccine Induced Thrombotic Immune Thrombocytopenia—A Case Report 

Coagulopathies after Vaccination against SARS-CoV-2 May Be Derived from a Combined Effect of SARS-CoV-2 Spike Protein and Adenovirus Vector-Triggered Signaling Pathways 

Thrombotic thrombocytopenic purpura: a new menace after COVID bnt162b2 vaccine 

Interactions of adenoviruses with platelets and coagulation and the vaccine-induced immune thrombotic thrombocytopenia syndrome  

Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT): Targeting Pathomechanisms with Bruton Tyrosine Kinase Inhibitors 

A Case of Idiopathic Thrombocytopenic Purpura After Booster Dose of BNT162b2 (Pfizer-Biontech) COVID-19 Vaccine 

A case of unusual mild clinical presentation of COVID-19 vaccine-induced immune thrombotic thrombocytopenia with splanchnic vein thrombosis 

Imaging of Oxford/AstraZeneca® COVID-19 vaccine-induced immune thrombotic thrombocytopenia 

Relapse of immune thrombocytopenia after COVID-19 vaccination 

Severe immune thrombocytopenia after COVID-19 vaccination: Report of four cases and review of the literature 

Thrombocytopenia in a teen with sickle cell disease following COVID-19 vaccination 

Newly diagnosed immune thrombocytopenia in a pregnant patient after coronavirus disease 2019 vaccination 

Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS) 

Intracerebral Hemorrhage and Thrombocytopenia After AstraZeneca COVID-19 Vaccine: Clinical and Diagnostic Challenges of Vaccine-Induced Thrombotic Thrombocytopenia 

Thrombocytopenia with acute ischemic stroke and bleeding in a patient newly vaccinated with an adenoviral vector-based COVID-19 vaccine 

Concern About the Adverse Effects of Thrombocytopenia and Thrombosis After Adenovirus-Vectored COVID-19 Vaccination  

A Case Report of Immune Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination 

Characteristics and Outcomes of Patients With Cerebral Venous Sinus Thrombosis in SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia 

Immune thrombocytopenia following immunisation with Vaxzevria ChadOx1-S (AstraZeneca) vaccine, Victoria, Australia 

COVID-19 Vaccine-Induced Thrombotic Thrombocytopenia: A Case Series 

A rare case of COVID-19 vaccine-induced thrombotic thrombocytopaenia (VITT) involving the veno-splanchnic and pulmonary arterial circulation, from a UK district general hospital 

Acute ST-segment elevation myocardial infarction secondary to vaccine-induced immune thrombosis with thrombocytopaenia (VITT) 

Refractory vaccine-induced immune thrombotic thrombocytopenia (VITT) managed with delayed therapeutic plasma exchange (TPE) 

Vaccine-induced immune thrombotic thrombocytopenia (VITT) – a novel clinico-pathological entity with heterogeneous clinical presentations 

VITT after ChAdOx1 nCoV-19 Vaccination 

Vaccine-Induced Thrombocytopenia with Severe Headache 

Thrombocytopenia in a teen with sickle cell disease following COVID-19 vaccination 

A case of vaccine-induced immune thrombotic thrombocytopenia with massive artero-venous thrombosis 

Secondary thrombocytopenia after SARS-CoV-2 vaccine: Report of a case of hemorrhage and hematoma after minor oral surgery Author links open overlay panel 

Neurosurgical Considerations Regarding Decompressive Craniectomy for Intracerebral Hemorrhage after SARS-CoV-2-Vaccination in Vaccine Induced Thrombotic Thrombocytopenia—VITT 

ChAdOx1 nCoV-19 vaccine-associated thrombocytopenia: three cases of immune thrombocytopenia after 107 720 doses of ChAdOx1 vaccination in Thailand   

An observational study to identify the prevalence of thrombocytopenia and anti-PF4/polyanion antibodies in Norwegian health care workers after COVID-19 vaccination 

Australian and New Zealand approach to diagnosis and management of vaccine-induced immune thrombosis and thrombocytopenia 

Vaccine-induced immune thrombotic thrombocytopenia (VITT) – a novel clinico-pathological entity with heterogeneous clinical presentations 

Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis 

Interactions of adenoviruses with platelets and coagulation and the vaccine-induced immune thrombotic thrombocytopenia syndrome 

Vaccine Induced Immune Thrombotic Thrombocytopenia Causing a Severe Form of Cerebral Venous Thrombosis With High Fatality Rate: A Case Series

Early Outcomes of Bivalirudin Therapy for Thrombotic Thrombocytopenia and Cerebral Venous Sinus Thrombosis After Ad26.COV2.S Vaccination 

The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic thrombocytopenia 

Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination 

Idiopathic Thrombocytopenic Purpura and the Moderna Covid-19 Vaccine 

Newly Diagnosed Idiopathic Thrombocytopenia Post COVID-19 Vaccine Administration 

Secondary immune thrombocytopenia supposedly attributable to COVID-19 vaccination 

Immune thrombocytopenia associated with Pfizer-BioNTech’s BNT162b2 mRNA COVID-19 vaccine 

Immune thrombocytopenia following vaccination during the COVID-19 pandemic 

COVID-19 vaccine, immune thrombotic thrombocytopenia, jaundice, hyperviscosity: concern on cases with underlying liver problem 

Transient Thrombocytopenia With Glycoprotein-Specific Platelet Autoantibodies After Ad26.COV2.S Vaccination: A Case Report 

Immune-Mediated Thrombocytopenia Associated With Ad26.COV2.S (Janssen; Johnson & Johnson) Vaccine 

Immune Thrombocytopenic Purpura Following Pfizer-BioNTech COVID-19 Vaccine in an Elderly Female 

Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopenia 

Acquired thrombotic thrombocytopenic purpura: A rare disease associated with BNT162b2 vaccine 

Vaccine-induced severe thrombotic thrombocytopenia following COVID-19 vaccination: a report of an autoptic case and review of the literature 

Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia 

Coronavirus (COVID-19) Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) 

Thrombotic Thrombocytopenia after COVID-19 Vaccination: In Search of the Underlying Mechanism 

Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis 

Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia 

Vaccine-induced thrombotic thrombocytopenia: the elusive link between thrombosis and adenovirus-based SARS-CoV-2 vaccines 

A case of thrombocytopenia and multiple thromboses after vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2 

Thrombocytopenia after COVID-19 vaccination 

Primary adrenal insufficiency associated with Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia (VITT) 

Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study 

Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study 

Diagnosis and Management of Cerebral Venous Sinus Thrombosis With Vaccine-Induced Immune Thrombotic Thrombocytopenia 

Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination 

Secondary Immune Thrombocytopenia (ITP) Associated with ChAdOx1 Covid-19 Vaccination – A Case Report 

Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine 

Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review 

Laboratory testing for suspected COVID-19 vaccine–induced (immune) thrombotic thrombocytopenia 

COVID-19 vaccine-associated immune thrombosis and thrombocytopenia (VITT): Diagnostic and therapeutic recommendations for a new syndrome 

Immune thrombocytopenia associated with Pfizer-BioNTech’s BNT162b2 mRNA COVID-19 vaccine 

Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia 

PF4 Immunoassays in Vaccine-Induced Thrombotic Thrombocytopenia 

Exacerbation of immune thrombocytopenia following COVID-19 vaccination 

Thrombosis With Thrombocytopenia After the Messenger RNA–1273 Vaccine 

Severe, Refractory Immune Thrombocytopenia Occurring After SARS-CoV-2 Vaccine 

Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination 

A COVID-Positive 52-Year-Old Man Presented With Venous Thromboembolism and Disseminated Intravascular Coagulation Following Johnson & Johnson Vaccination: A Case-Study 

Concerning the unexpected prothrombotic state following some coronavirus disease 2019 vaccines 

Thrombotic Adverse Events Reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 Vaccines: Comparison of Occurrence and Clinical Outcomes in the EudraVigilance Database 

Immune thrombocytopenic purpura associated with COVID-19 Pfizer-BioNTech BNT16B2b2 mRNA vaccine 

Idiopathic Ipsilateral External Jugular Vein Thrombophlebitis After Coronavirus Disease (COVID-19) Vaccination Read More: https://www.ajronline.org/doi/10.2214/AJR.21.25708 

Change of blood viscosity after COVID-19 vaccination: estimation for persons with underlying metabolic syndrome 

Dyp venetrombose mer enn to uker etter vaksinering mot covid-19 

Oxford-AstraZeneca COVID-19 vaccine-induced cerebral venous thrombosis and thrombocytopaenia: A missed opportunity for a rapid return of experience 

mRNA COVID-19 Vaccine–Related Anaphylactoid Reaction and Coronary Thrombosis 

CAd26.COV2‑S vaccination can reveal inherited thrombophilia: a case of massive cerebral venous sinus thrombosis in a young man with normal platelet count 

Clinical and biological features of cerebral venous sinus thrombosis following ChAdOx1 nCov-19 vaccination 

COVID-19 vaccine-induced thrombosis 

Three cases of acute venous thromboembolism in females after vaccination for coronavirus disease 2019 

Deep Venous Thrombosis after Ad26.COV2.S Vaccination in Adult Male 

Unusual Site of Deep Vein Thrombosis After mRNA Coronavirus Disease-2019 (COVID-19) Vaccination 

Thrombosis After Adenovirus-Vectored COVID-19 Vaccination: A Concern on Underlying Illness 

Possible Risk of Thrombotic Events following Oxford-AstraZeneca COVID-19 Vaccination in Women Receiving Estrogen 

Thromboembolic events in younger women exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines 

Thrombotic Thrombocytopenic Purpura after Ad26.COV2-S Vaccination 

Cerebral Venous Sinus Thrombosis After Pfizer-BioNTech COVID-19 (BNT162b2) Vaccination 

Cerebral Venous Sinus Thrombosis After BNT162b2 mRNA COVID-19 Vaccination 

New Portal Vein Thrombosis in Cirrhosis – is the Thrombophilia Exacerbated due to Vaccine or COVID-19? 

Autoimmunity roots of the thrombotic events after COVID-19 vaccination 

Cerebral Venous Sinus Thrombosis and Thrombotic Events After Vector-Based COVID-19 Vaccines 

Cerebral Venous Sinus Thrombosis, Pulmonary Embolism, and Thrombocytopenia After COVID-19 Vaccination in a Taiwanese Man: A Case Report and Literature Review 

Imaging and Hematologic Findings in Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 (AstraZeneca) Vaccination 

Thrombosis formation after COVID-19 vaccination Immunological Aspects: Review article 

An unusual presentation of acute deep vein thrombosis after the Moderna COVID-19 vaccine—a case report 

Vaccine-Associated Thrombocytopenia and Thrombosis: Venous Endotheliopathy Leading to Venous Combined Micro-Macrothrombosis 

Thrombosis in pre- and post-vaccination phase of COVID-19 

Comments on Thrombosis After Vaccination: The Leader Sequence of the Spike Protein Might Be Responsible for Thrombosis and Antibody-Mediated Thrombocytopenia 

Understanding risk of thrombosis with thrombocytopenia syndrome after Ad26.COV2.S vaccination 

Thromboses of major arteries and ChAdOx1 nCov-19 vaccination 

Venous Thromboembolism and Mild Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination 

Response to bilateral adrenal haemorrhage in the differential diagnosis of abdominal pain in vaccine-induced thrombosis with thrombocytopenia 

Thrombosis post COVID-19 vaccinations: Potential link to ACE pathways 

Thrombosis in peripheral artery disease and thrombotic thrombocytopenia after adenoviral COVID-19 vaccination 

Vaccine-induced immune thrombosis and thrombocytopenia syndrome following adenovirus-vectored severe acute respiratory syndrome coronavirus 2 vaccination: a novel hypothesis regarding mechanisms and implications for future vaccine development 

Case report: cerebral sinus vein thrombosis in two patients with AstraZeneca SARS-CoV-2 vaccination 

Hirnvenen- und Sinusthrombose nach COVID-19-Schutzimpfung 

COVID-19 Vaccine-Associated Thrombosis With Thrombocytopenia Syndrome (TTS): A Systematic Review and Post Hoc Analysis 

Cerebral venous sinus thrombosis after ChAdOx1 vaccination: the first case of definite thrombosis with thrombocytopenia syndrome from India 

Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines 

Case study of thrombosis and thrombocytopenia syndrome following administration of the AstraZeneca COVID-19 vaccine 

COVID-19 Vaccine-Induced Immune Thrombosis with Thrombocytopenia (VITT) and the Shades of Grey in Thrombus Formation 

Cerebral venous sinus thrombosis after mRNA-based COVID-19 vaccination 

Genital necrosis with cutaneous thrombosis after COVID-19 mRNA vaccination 

Age- and Sex-Specific Incidence of Cerebral Venous Sinus Thrombosis Associated With Ad26.COV2.S COVID-19 Vaccination 

Intracerebral hemorrhage associated with vaccine-induced thrombotic thrombocytopenia following ChAdOx1 nCOVID-19 vaccine in a pregnant woman 

Thrombotic Events after COVID-19 Vaccination in the Over-50s: Results from a Population-Based Study in Italy 

Neuro-ophthalmic complications with ChAdOx1 nCoV-19 vaccine-induced thrombocytopenia and thrombosis 

A case series of vaccine-induced thrombotic thrombocytopenia in a London teaching hospital 

Multiple Sites of Arterial Thrombosis in A 35-Year Old Patient after ChAdOx1 (AstraZeneca) Vaccination, Requiring Emergent Femoral and Carotid Surgical Thrombectomy 

Potential Triggers for Thrombocytopenia and/or Hemorrhage by the BNT162b2 Vaccine, Pfizer-BioNTech

Cerebral venous thrombosis and myeloproliferative neoplasms: A three-center study of 74 consecutive cases 

Cerebral Venous Thrombosis Developing after COVID-19 Vaccination: VITT, VATT, TTS, and More 

Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: the FAPIC score 

Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis 

Delayed headache after COVID-19 vaccination: a red flag for vaccine induced cerebral venous thrombosis 

Portal Vein Thrombosis due to Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) after Covid Vaccination with ChAdOx1 nCoV-19 

Cerebral vein/venous sinus thrombosis with thrombocytopenia syndrome after COVID-19 vaccination 

Cerebral venous sinus thrombosis after vaccination: the UK experience 

ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome 

Cutaneous thrombosis associated with skin necrosis following Oxford-AstraZeneca COVID-19 vaccination 

Massive cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia 

Intracerebral hemorrhage associated with vaccine-induced thrombotic thrombocytopenia following ChAdOx1 nCOVID-19 vaccine in a pregnant woman 

Venous Thromboembolism and Mild Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination 

Renal Vein Thrombosis and Pulmonary Embolism Secondary to Vaccine-induced Thrombotic Thrombocytopenia (VITT) 

Thrombosis and severe acute respiratory syndrome coronavirus 2 vaccines: vaccine-induced immune thrombotic thrombocytopenia 

A rare case of superior ophthalmic vein thrombosis and thrombocytopenia following ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 

First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland 

Predicted and Observed Incidence of Thromboembolic Events among Koreans Vaccinated with ChAdOx1 nCoV-19 Vaccine 

Massive cerebral venous thrombosis and venous watershed infarction as late complications of COVID-19: a case report 

Cerebral venous sinus thrombosis after vaccination: the UK experience 

Autoimmunity roots of the thrombotic events after COVID-19 vaccination 

Imaging and Hematologic Findings in Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 (AstraZeneca) Vaccination 

US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021 

Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study 

Cerebral venous sinus thrombosis 2 weeks after the first dose of mRNA SARS-CoV-2 vaccine 

Anti-PF4 antibody negative cerebral venous sinus thrombosis without thrombocytopenia following immunization with COVID-19 vaccine in an elderly non-comorbid Indian male, managed with conventional heparin-warfarin based anticoagulation 

Middle-age Asian male with cerebral venous thrombosis after COVID-19 AstraZeneca vaccination 

Post-SARS-CoV-2-vaccination cerebral venous sinus thrombosis: an analysis of cases notified to the European Medicines Agency 

Reported adverse effects following COVID-19 vaccination at a tertiary care hospital, focus on cerebral venous sinus thrombosis (CVST) 

Cerebral venous sinus thrombosis associated with thrombocytopenia post-vaccination for COVID-19 

Cerebral venous sinus thrombosis after ChAdOx1 nCov-19 vaccination with a misleading first cerebral MRI scan 

Cerebral venous thrombosis after COVID-19 vaccination: is the risk of thrombosis increased by intravascular application of the vaccine? 

Cerebral Venous Sinus Thrombosis in the U.S. Population, After Adenovirus-Based SARS-CoV-2 Vaccination, and After COVID-19 

Fatal cerebral venous sinus thrombosis after COVID-19 vaccination 

Cerebral Venous Thrombosis following COVID-19 Vaccination 

Cerebral Venous Thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine 

Cerebral venous sinus thrombosis associated with vaccine-induced thrombotic thrombocytopenia 

Adenovirus-Vectored COVID-19 Vaccine–Induced Immune Thrombosis of Carotid Artery 

SARS-CoV-2 vaccine-induced cerebral venous thrombosis 

Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination – A report of two UK cases 

Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Postvaccination ASIA Syndrome 

Tolosa-Hunt Syndrome Presenting After COVID-19 Vaccination 

Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis 

Endovascular treatment for vaccine-induced cerebral venous sinus thrombosis and thrombocytopenia following ChAdOx1 nCoV-19 vaccination: a report of three cases 

Treatment of ChAdOx1 nCoV-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia Related Acute Ischemic Stroke 

Type I interferons as the potential mechanism linking mRNA COVID-19 vaccines to Bell’s palsy 

Lipschütz Ulcers after the AstraZeneca COVID-19 Vaccine 

Case of immunoglobulin A vasculitis following coronavirus disease 2019 vaccination 

Cutaneous small vessel vasculitis following single-dose Janssen Ad26.COV2.S vaccination 

Flares of mixed cryoglobulinaemia vasculitis after vaccination against SARS-CoV-2 

Leukocytoclastic vasculitis after coronavirus disease 2019 vaccination 

Cutaneous vasculitis after severe acute respiratory syndrome coronavirus 2 vaccine 

Relapse of microscopic polyangiitis after vaccination against COVID-19: A case report 

Granulomatous vasculitis after the AstraZeneca anti–SARS-CoV-2 vaccine 

Henoch-Schönlein Purpura Following the First Dose of COVID-19 Viral Vector Vaccine: A Case Report 

Asymmetrical cutaneous vasculitis following COVID-19 vaccination with unusual eosinophil preponderance 

Emergence of de novo cutaneous vasculitis post coronavirus disease (COVID-19) vaccination 

First description of immune complex vasculitis after COVID-19 vaccination with BNT162b2: a case report 

Reactivation of IgA vasculitis after COVID-19 vaccination 

Coronavirus disease 2019 (COVID-19) vaccination in systemic lupus erythematosus and anti-neutrophil cytoplasmic antibody-associated vasculitis 

Propylthiouracil-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis after COVID-19 Vaccination 

Possible case of mRNA COVID-19 vaccine-induced small-vessel vasculitis 

Cutaneous vasculitis following COVID-19 vaccination 

Images in Vascular Medicine: Leukocytoclastic vasculitis after COVID-19 vaccine booster 

Small vessel vasculitis related to varicella-zoster virus after Pfizer-BioNTech COVID-19 vaccine 

Reactivation of IgA vasculitis following COVID-19 vaccination 

Case Report: ANCA-Associated Vasculitis Presenting With Rhabdomyolysis and Pauci-Immune Crescentic Glomerulonephritis After Pfizer-BioNTech COVID-19 mRNA Vaccination 

Cutaneous lymphocytic vasculitis after administration of COVID-19 mRNA vaccine 

Vasculitis and bursitis on [18F]FDG-PET/CT following COVID-19 mRNA vaccine: post hoc ergo propter hoc? 

Leukocytoclastic vasculitis flare following the COVID-19 vaccine 

Cutaneous small-vessel vasculitis following COVID-19 vaccine 

New-onset leukocytoclastic vasculitis after COVID-19 vaccine 

ANCA-Associated Vasculitis Following Pfizer-BioNTech COVID-19 Vaccine 

COVID-19 vaccine-induced urticarial vasculitis 

Intracerebral hemorrhage due to vasculitis following COVID-19 vaccination: a case report 

Case Report: Anti-neutrophil Cytoplasmic Antibody-Associated Vasculitis With Acute Renal Failure and Pulmonary Hemorrhage May Occur After COVID-19 Vaccination

Cutaneous Lymphocytic Vasculitis After Administration of the Second Dose of AZD1222 (Oxford–AstraZeneca) Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination: Casuality or Causality? 

Relapsed ANCA associated vasculitis following Oxford AstraZeneca ChAdOx1-S COVID-19 vaccination: A case series of two patients 

Cutaneous Leukocytoclastic Vasculitis Induction Following ChAdOx1 nCoV-19 Vaccine 

Leukocytoclastic vasculitis as a cutaneous manifestation of ChAdOx1 nCoV-19 corona virus vaccine (recombinant) 

A case of ANCA-associated vasculitis after AZD1222 (Oxford–AstraZeneca) SARS-CoV-2 vaccination: casualty or causality? 

Leukocytoclastic Vasculitis After Vaccination With a SARS-CoV-2 Vaccine 

IgA vasculitis in adult patient following vaccination by ChadOx1 nCoV-19 

Propylthiouracil-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis after COVID-19 Vaccination 

ANCA-Associated Vasculitis Following Pfizer-BioNTech COVID-19 Vaccine 

Reactivation of Vogt-Koyanagi-Harada disease under control for more than 6 years, following anti-SARS-CoV-2 vaccination 

Vogt-Koyanagi-Harada Syndrome following COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccine